Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man

Critical Reviews in Oncology/Hematology

Volumn 46, Issue 2, 2003, Pages 139-163

  Slavin, Shimon ^a   Morecki, Shoshana ^a   Weiss, Lola ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic cell mediated immunotherapy; Bone marrow transplantation (BMT); Cytokine mediated immunotherapy; Interferon alpha (IFN); Recombinant human interleukin 2 (rIL 2); Stem cell transplantation; Transplantation tolerance

Indexed keywords

ALLOANTIGEN; ANTINEOPLASTIC AGENT; CYTOKINE; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CLONOGENIC ASSAY; CONDITIONING; DRUG MEGADOSE; DRUG TOLERANCE; EXPERIMENTAL TEST; GRAFT VERSUS HOST REACTION; HEALTH HAZARD; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INOCULATION; LEUKEMIA REMISSION; LYMPHOCYTE; METASTASIS; MINIMAL RESIDUAL DISEASE; MYELOBLAST; NONHUMAN; OBSERVATION; ORGAN DONOR; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; SURGICAL TECHNIQUE; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 0037404069     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00108-7     Document Type: Review

References (126)

1. Thomas E.D. Marrow transplantation for malignant diseases. J. Clin. Oncol. 1:1983;517-531.
2. Gratwohl A., Hermans J., Goldman J.M., et al. Chronic leukemia. Lancet. 352:1998;1087.
3. Passweg J.R., Rowlings P.A., Armitage J.O., et al. Cecka J.M., Teraskaki P.I. Report from the international bone marrow transplant registry and autologous blood and marrow transplant registry - North America. Clinical transplants, 1995. 1996;117-127 UCLA Tissue Typing Laboratory, Los Angeles, California.
4. Bast C.R. Principles of cancer biology: tumour immunology. DeVitta V.T., Hellman S., Rosenberg S.A. Cancer; principles & practice of oncology. 1985;125-141 J.B. Lippincott Company, Philadelphia.
5. Weiss L., Lubin I., Factorowich Y., et al. Effective graft vs leukemia effects independent of graft vs host disease after T-Cell depleted allogeneic bone marrow transplantation in a murine model of B Cell leukemia/lymphoma. Role of cell therapy and rIL-2. J. Immunol. 153:(6):1994;2562-2567.
6. Grillo-Lopez A.J., White C.A., Dallaire B.K., et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol. 1:(1):2000;1-9. Review.
7. Thomas E.D. The role of marrow transplantation in the eradication of malignant disease. Cancer. 49:1963;1963-1968.
8. Weiden P.L., Sullivan K.M., Fluornoy N., Strob R., Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl. J. Med. 304:1981;1529-1533.
9. Weiden P.L., Fluornoy N., Sanders J.E., Sullivan K.M., Thomas E.D. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation. 13:1981;248-251.
10. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 73:1989;1720-1726.
11. Horowitz M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555-562.
12. Sinkovics J.G., Shullenberger C.C., Howe C.D. Prolongation and prevention of Rauscher virus mouse leukemia by spleen cells of naturally resistant or actively immunized mice. Clin. Res. 13:1965;36-39.
13. Boranic M., Tonkovic I. Time pattern of the antileukemia effect of graft-versus-host reaction in mice, I. Cellular events. Cancer Res. 31:1971;1140-1147.
14. Bortin M.M., Truitt R.L., Rimm A.A., Bach F.H. Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature. 281:1979;490-491.
15. Slavin S., Weiss L., Morecki S., Weingensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol. Immunother. 11:1981;155-161.
16. Truitt R.L., Shih F.-H., LeFever A.V., Tempelis L.D., Andreani M., Bortin M.M. Characterization of alloimmunization-induced T lymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J. Immunol. 131:1983;2050-2058.
17. Meredith R.F., O'Kunewick J.P. Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation. Transplantation. 35:1983;378-385.
18. Weiss L., Weigensberg M., Morecki S., et al. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol. Immunother. 31:1990;236-242.
19. Truitt R.L., Atasoylu A.A. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation. Blood. 77:1991;2515-2523.
20. Moscovitch M., Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB×NZW)F1 hybrids with spontaneous lymphosarcoma. J. Immunol. 132:1984;997-1000.
21. Morecki S., Moshel Y., Gelfend Y., et al. Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma. Int. J. Cancer. 71:1997;59-63.
22. Morecki S., Yacovlev E., Diab A., Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 58:1998;3891-3895.
23. Eibl B., Schwaighofer H., Nachbaur D., et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 88:1996;1501-1508.
24. Ueno N.T., Rondón G., Mirza N.Q., et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J. Clin. Oncol. 16:1998;986-993.
25. Or R, Ackerstein A, Nagler A, et al. Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study, Cytokines, Cellular & Molecular Therapy 1998;4:1-6.
26. Higano C.S., Brixey M., Bryant E.M. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow tranplantation. A case report of a probable graft-versus-leukemia effect. Transfusion. 50:1990;175-178.
27. Bacigalupo A., Van Lint M.T., Occhini D., et al. Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 77:1991;1423.
28. Weiss L., Reich S., Slavin S. Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant. 6:1990;229-233.
29. Kapelushnik J., Or R., Aker M., et al. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant. 19:1996;96-98.
30. Kapelushnik J., Aker M., Or R., et al. Allogeneic cell therapy as a new modality for displacement of genetically abnormal stem cells as part of the conditioning for allogeneic bone marrow transplantation.Correction of genetic diseases by transplantation. 1997;111-119 Cogent Press. Chapter 4.
31. Aker M., Kapelushnik J., Pugatsch T., et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT for beta thalassemia major. J. Pediatr. Hematol./Oncol. 20:(2):1998;145-148.
32. Slavin S., Nagler A., Naparstek E., et al. Minitransplants and cell-based therapies for malignant and non-malignant disorders. Curr. Opin. Organ Transplant. 4:(3):1999;184-188.
33. Slavin S., Or R., Naparstek E., Ackerstein A., Weiss L. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood. 72:(suppl 1):1988;407a.
34. Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik Y., Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp. Hematol. 23:1995;1553-1562.
35. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood. 87:1996;2195-2204.
36. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465.
37. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for blood and marrow transplantation. Blood. 86:1995;2041-2050.
38. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:1997;433-444.
39. Porter D.L., Roth M.S., McGarigle C., et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl. J. Med. 330:1994;100-106.
40. Mackinnon S., Papadopoulos E.B., Carabassi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 86:1995;1261-1268.
41. Gubbay I., Collignon J., Koopman P., et al. A gene mapping to the sex-determining region of the mouse y chromosome is a member of a novel family of embryologically expressed genes. Nature. 346:1990;245-250.
42. Pugatsch T., Oppenheim A., Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant. 17:1996;273-275.
43. Kawasaki E.S., Clark S.S., Coyne M.Y., et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. PNAS. 85:1988;5698-5702.
44. De Witte T., Schattenberg A., Preijers F., Mensink E. Treatment of relapse in recipients of lymphocyte depleted grafts with infusion of lymphocytes of the original bone marrow donor. Exp. Hematol. 20:1992;723.
45. Bar B.M., Schattenberg A., Mensink E.J., et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 11:1993;513-519.
46. Leber B., Walker I.R., Rodrigues A., McBride J.A., Carter R., Brian M.C. Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant. 12:1993;405-407.
47. Papadopoulos E.B., Ladanyi M., Emanual D., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lympho-proliferative disorders after allogeneic bone marrow transplantation. New Engl. J. Med. 330:1994;1185-1191.
48. Kuzushima K., Yamamoto M., Kimura H., et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus specific cytotoxic T lymphocytes from an HLA matched sibling to a patient with severe chronic active EBV infection. Clin. Exp. Immunol. 103:1996;192-198.
49. Stockschlaeder M., Storb R., Pepe M., et al. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br. J. Haematol. 80:1992;49-54.
50. Odom L.F., August C.S., Githens J.H., et al. Remmission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versus-leukaemia reaction' in man. Lancet. 2:1978;537-538.
51. Slavin S., Fuks Z., Kaplan H.S., Strober S. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J. Exp. Med. 147:1978;963-972.
52. Weiss L., Reich S., Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest. 10:1992;19-26.
53. Johnson B.D., Drobyski W.R., Truitt R.L. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant. 11:1993;329-336.
54. Naparstek E., Or R., Nagler A., et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br. J. Haematol. 89:1995;506-515.
55. Naparstek E., Nagler A., Or R., Slavin S. Cecka J.M., Teraskaki P.I. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. North America. Clinical transplants, 1995. 1996;281-290 UCLA Tissue Typing Laboratory, Los Angeles, California.
56. van Rhee F., Lin F., Cullis J.O., et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematological relapse. Blood. 83:(11):1994;3377-3383.
57. Sullivan K.M., Storb R., Buckner C.D., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New Engl. J. Med. 320:1989;828-834.
58. Rosenberg S.A. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10:1992;180-192.
59. Van Lochem E., De Gast B., Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic-T cell activities. Bone Marrow Transplant. 10:1992;181-183.
60. Falkenburg J.H.F., Faber L.M., van den Elshout M., et al. Generation of donor derived antileukemic cytotoxic T lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA identical bone marrow transplantation. J. Immunother. 14:1993;305.
61. Slavin S., Ackerstein A., Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation-amplification of natural host defence mechanisms against cancer by recombinant IL2. Natural Immunity & Cell Growth Regul. 7:1988;180-184.
62. Nagler A., Ackerstein A., Or R., Naparstek E., Slavin S. Immunotherapy with recombinant human interleukin-2 (rIL-2) and recombinant α-interferon in lymphoma patients post autologous marrow or stem cell transplantation. Blood. 89:(11):1997;3951-3959.
63. Nagler A., Ackerstein A., Barak V., Slavin S. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-2a. J. Hematother. 3:1994;75-82.
64. Ackerstein A., Kedar E., Slavin S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. Blood. 78:1991;1212-1215.
65. Weiss L., Weigensberg M., Morecki S., et al. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol. Immunother. 31:1990;236-242.
66. Slavin S, Ackerstein A, Morecki S, Gelfand Y, Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes, Bone Marrow Transplant. 2001;28:795-8.
67. Weiss L., Reich S., Slavin S. The role of non-activated and rIL-2 activated CD4+ and CD8+ T cells in immunotherapy for leukemia. Cytokines, Cell. Mol. Therapy. 5:1999;153-158.
68. Weiss L., Reich S., Slavin S. Effect of deoxyspergualin on graft vs host disease and graft vs leukemia in mice. Bone Marrow Transplant. 17:1996;789-792.
69. Weiss L., Reich S., Slavin S. The role of antibodies to IL-2 receptor and anti-Asialo GMI antibodies on GVL effects induced by BMT in murine B cell leukemia. Bone Marrow Transplant. 16:(3):1995;457-461.
70. Palathumpat V., Dejbakhsh-Jones S., Strober S. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation. 60:(4):1995;355-361.
71. Korngold R., Leighton C., Manser T. Graft-vs-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation. 58:(3):1994;278-287.
72. Zeis M., Uharek L., Glass B., et al. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukemia effect in mice. Br. J. Haematol. 96:1997;757.
73. Greenberg P.D. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:1991;281.
74. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 94:(1):1999;333-339.
75. Giralt S., Hester J., Huh Y., et al. CD8-depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 86:1995;4337-4343.
76. Collins R.H., Rogers Z.R., Bennett M., Kurser V., Nikein A., Fay J.W. Hematologic relapse of chronic myelogenous leukemia following abrupt discontinuation of immunosuppression. Bone Marrow Transplant. 10:1992;391-395.
77. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. 157:1997;125-140.
78. Mutis T., Verdijk R., Schrama E., Esendam B., Brand A., Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 93:1999;2336-2341.
79. Cudkowicz G., Rossi G.B. Hybrid resistance to parental DBA-2 grafts: independence from the H-2 locus. I. Studies with normal hematopoietic cells. J. Natl. Cancer Inst. 48:(1):1972;131-139.
80. Ringden O., Horowitz M.M. Graft-vs-leukemia reactions in humans. Transplant Proc. 21:1989;2989.
81. Reisner Y., Kapoor N., et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 61:(2):1983;341-348.
82. Waldmann H., Polliack A., Hale G., et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet. 2:1984;483-485.
83. Reisner Y., Martelli M.F. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol. Today. 16:1995;437.
84. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl. J. Med. 339:1998;1186-1193.
85. Slavin S., Strober S. Spontaneous murine B-cell leukemia. Nature. 272:1978;624.
86. Slavin S., Weiss L., Morecki S., et al. Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. Cancer Res. 41:1981;4162-4166.
87. Raanani P., Dazzi F., Sohal J., et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br. J. Haematol. 99:(4):1997;945-950.
88. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft-vs-host disease; the role of gastrointestinal damage and inflammatory cytokines. Blood. 90:1997;3204-3213.
89. Kolb H.J., Beisser K., Holler E., et al. Donor buffy coat transfusion for adoptive immunotherapy in human and canine chimeras. Periodicum Biologorum. 93:1991;81.
90. Slavin S., Waldmann H., Or R., et al. Prevention of graft vs host disease in allogeneic bone marrow transplantation for leukemia by T cell depletion in vitro prior to transplantation. Transplant Proc. 17:1985;465-467.
91. Cobold S., Martin G., Waldmann H. Monoclonal antibodies for the prevention of graft versus host disease and marrow graft rejection. Transplantation. 42:1986;239.
92. Hale G., Xia M.Q., Tighe H.P., Dyer M.J.S., Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens. 35:1990;118.
93. Naparstek E., Or R., Nagler A., et al. Allogeneic BMT for leukemia using Campath-1 monoclonal antibodies & post transplant alloimmunization with donor lymphocytes. Exp. Hematol. 21:1993;1061. Abs. 189.
94. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocyte for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft versus leukemia response from graft versus disease. Blood. 86:1995;1261.
95. Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science. 276:1997;1719-1724.
96. Passweg J.R., Rowlings P.A., Armitage J.O., et al. Cecka J.M., Teraskaki P.I. Report from the international bone marrow transplant registry and autologous blood and marrow transplant registry - North America. Clinical transplants, 1995. 1996;117-127 UCLA Tissue Typing Laboratory, Los Angeles, California.
97. Carella A.M., Giralt S., Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica. 85:(3):2000;304-313.
98. Carella A.M., Champlin R., Slavin S., McSweeney P., Strob R. 'Mini-allografts': ongoing trials in humans. Bone Marrow Transplant. 25:(4):2000;345-350.
99. Slavin S., Nagler A., Naparstek E., et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood. 91:(3):1998;756-763.
100. Nagler A., Slavin S., Varadi G., Naparstek E., Samuel S., Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for a malignant lymphoma. Bone Marrow Transplant. 25:(10):2000;1021-1028.
101. Kapelushnik J., Aker M., Pugatsch T., Samuel S., Slavin S. Bone marrow transplatation from a cadaveric donor. Bone Marrow Transplant. 21:(8):1998;857-858.
102. Nagler A., Ackerstein A., Kapelushnik J., Or R., Naparstek E., Slavin S. Donor lymphocyte infusion post non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant. 24:1999;339-342.
103. Kapelushnik J., Or R., Slavin S., Nagler A. Fludarabine based protocol for BMT in Fanconi anemia. Bone Marrow Transplant. 29:(12):1997;1109-1110.
104. Aker A., Varadi G., Slavin S., Nagler A. A fludarabine based nonmyeloablative protocol for human umbilical cord blood transplantation in Fanconi's anemia. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi's anemia. J. Pediatr. Hematol. Oncol. 21:(3):1999;237-239.
105. Nagler A., Aker M., Or R., et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp. Hematol. 29:2001;362-370.
106. Slavin S. Total lymphoid irradiation (TLI). Immunol. Today. 8:1987;88-92.
107. Ildstad S.T., Sachs D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts and xenografts. Nature. 307:1984;168.
108. Sykes M., Sachs D.H. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol. Today. 9:1988;23.
109. Weiss L., Slavin S. Prevention and treatment of graft vs host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant. 23:1999;1139-1143.
110. Prigozhina T., Gurevitch O., Slavin S. Non-myeloblative conditioning to induce tolerance after allogeneic bone marrow transplantation in mice. Exp. Hematol. 27:1999;1503-1510.
111. Storb R., Raff R.F., Appelbaum F.R., et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood. 74:1989;1139.
112. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 89:1997;3048.
113. Yu C., Storb R., Mathey B., et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood. 86:1995;4376-4381.
114. Storb R., Yu C., Barnett T., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given lymph node irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 90:1999;1131-1136.
115. Storb R, Yu C, Zaucha JM, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy TBI before and pharmacological immunosuppression after marrow transplant, Blood 1994;94(7):2523-9.
116. McSweeney P.A., Wagner J.L., Maloney D.G., et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood. 92:(Suppl 1):1998;519a. (abstr. 2133).
117. Giralt S., Gajewski J., Khouri I., et al. Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia. Blood. 90:(suppl.1):1997;1857a.
118. Giralt S., Cohen A., Mehra R., et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenito cell transplantation in poor candidates for conventional myeloablative conditioning. Blood. 90:(suppl.1):1997;1853a.
119. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16:1998;2817-2824.
120. Childs R.W., Clave E., Tisdale J., et al. Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J. Clin. Oncol. 17:1999;2044-2050.
121. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Engl. J. Med. 14, 343:(11):2000;750-758.
122. Sykes M., Preffer F., McAfee S., et al. Mixed lymphohematopoietic chimerism and graft versus lymphoma effect are achievable in adult recipients following non-myeloablative therapy and HLA-mismatched donor bone marrow transplantation. The Lancet. 353:1999;1755-1759.
123. Carella A.M., Lerma E., Dejana A., et al. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica. 83:1998;904-909.
124. Carella A.M., Lerma E., Corsetti M.T., et al. Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. Br. J. Haematol. 103:1998;565-567.
125. Morecki S., Yacovlev E., Gelfand Y., Uzi I., Slavin S. Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J. Immunother. 24:(2):2001;114-121.
126. Rosenberg S.A., Lotze M.T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Ann. Rev. Immunol. 4:1986;681-709.